Memorial Sloan Kettering Cancer Center (MSK) is a free-standing NCI-designated Comprehensive Cancer Center dedicated to improving the standards of cancer treatment, prevention and control. MSK?s research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Structural and Chemical Biology); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Population Science Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators. MSK seeks to encourage the application of scientific discoveries in a way that advances the prevention, detection, diagnosis, and treatment of the many forms of cancer that are relevant to the population in our catchment area. Scientific work in the 10 research programs depends on services provided by 26 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 20 of these core facilities. Over the next five years, MSK will continue to enhance its clinical and research facilities and its research and training programs in emerging research areas. Support is requested to provide developmental funding for the support of newly recruited investigators in computational biology, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Public Health Relevance

Memorial Sloan Kettering Cancer Center (MSK) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities. Through these activities, MSK seeks to reduce the burden of cancer throughout our catchment area and the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084809
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Fleshner, Katherine; Carlsson, Sigrid V (2018) The USPSTF screening recommendation: a swinging pendulum. Nat Rev Urol 15:532-534
Weingart, Saul N; Atoria, Coral L; Pfister, David et al. (2018) Risk Factors for Adverse Events in Patients With Breast, Colorectal, and Lung Cancer. J Patient Saf :
Henry, Kelly E; Ulaner, Gary A; Lewis, Jason S (2018) Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer. PET Clin 13:423-435
Adams, Nicholas M; Sun, Joseph C (2018) Spatial and temporal coordination of antiviral responses by group 1 ILCs. Immunol Rev 286:23-36
Sidhom, John-William; Bessell, Catherine A; Havel, Jonathan J et al. (2018) ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis. Cancer Immunol Res 6:151-162
Roxburgh, Campbell S; Weiser, Martin R (2018) Selective use of radiation for locally advanced rectal cancer: one size does not fit all. Minerva Chir 73:592-600
Roobol, Monique J; Carlsson, Sigrid V (2018) The ERSPC Study: Quality Takes Time and Perseverance. Clin Chem :
Hu, Zishuo Ian; Hellmann, Matthew D; Wolchok, Jedd D et al. (2018) Acquired resistance to immunotherapy in MMR-D pancreatic cancer. J Immunother Cancer 6:127
Warren, Shay; Kheterpal, Meenal; Myskowski, Patricia L et al. (2018) Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. J Am Acad Dermatol 78:530-539
Sanchez, Ana M; Shuman, Stewart; Schwer, Beate (2018) Poly(A) site choice and Pol2 CTD Serine-5 status govern lncRNA control of phosphate-responsive tgp1 gene expression in fission yeast. RNA 24:237-250

Showing the most recent 10 out of 8799 publications